Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

医学 吉非替尼 内科学 安慰剂 危险系数 临床终点 肺癌 人口 养生 胃肠病学 腺癌 外科 随机对照试验 癌症 置信区间 表皮生长因子受体 病理 替代医学 环境卫生
作者
Nick Thatcher,Alex Y. Chang,Purvish M. Parikh,José Rodrigues Pereira,Tudor‐Eliade Ciuleanu,Joachim von Pawel,Sumitra Thongprasert,E.H. Tan,Kristine Pemberton,Venice Archer,Kevin Carroll
出处
期刊:The Lancet [Elsevier BV]
卷期号:366 (9496): 1527-1537 被引量:2105
标识
DOI:10.1016/s0140-6736(05)67625-8
摘要

Background This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer. Methods 1692 patients who were refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio of two to one either gefitinib (250 mg/day) or placebo, plus best supportive care. The primary endpoint was survival in the overall population of patients and those with adenocarcinoma. The primary analysis of the population for survival was by intention to treat. This study has been submitted for registration with ClinicalTrials.gov, number 1839IL/709. Findings 1129 patients were assigned gefitinib and 563 placebo. At median follow-up of 7·2 months, median survival did not differ significantly between the groups in the overall population (5·6 months for gefitinib and 5·1 months for placebo; hazard ratio 0·89 [95% CI 0·77–1·02], p=0·087) or among the 812 patients with adenocarcinoma (6·3 months vs 5·4 months; 0·84 [0·68–1·03], p=0·089). Preplanned subgroup analyses showed significantly longer survival in the gefitinib group than the placebo group for never-smokers (n=375; 0·67 [0·49–0·92], p=0·012; median survival 8·9 vs 6·1 months) and patients of Asian origin (n=342; 0·66 [0·48–0·91], p=0·01; median survival 9·5 vs 5·5 months). Gefitinib was well tolerated, as in previous studies. Interpretation Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population. There was pronounced heterogeneity in survival outcomes between groups of patients, with some evidence of benefit among never-smokers and patients of Asian origin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
踏实啤酒完成签到 ,获得积分10
刚刚
戴岱发布了新的文献求助10
1秒前
可爱的函函应助Dadonnggua采纳,获得10
2秒前
7秒前
善学以致用应助Fox采纳,获得10
7秒前
三两白菜完成签到,获得积分10
12秒前
12秒前
嗷嗷嗷啊发布了新的文献求助20
12秒前
SYLH应助linguobin采纳,获得10
13秒前
积极的夜香完成签到,获得积分20
15秒前
辛云完成签到,获得积分10
16秒前
受伤幻桃发布了新的文献求助10
16秒前
我是老大应助catalm采纳,获得10
16秒前
16秒前
16秒前
奥里给医学生完成签到 ,获得积分10
19秒前
19秒前
Fox发布了新的文献求助10
19秒前
20秒前
CodeCraft应助slj采纳,获得10
22秒前
英姑应助阿星捌采纳,获得10
22秒前
TMOMOR应助HHHAN采纳,获得10
23秒前
Perfection发布了新的文献求助10
23秒前
吴玉婷完成签到,获得积分10
23秒前
23秒前
23秒前
阔达的水壶完成签到 ,获得积分10
27秒前
27秒前
魔幻问薇完成签到 ,获得积分10
28秒前
何1完成签到,获得积分10
28秒前
大勺完成签到 ,获得积分10
28秒前
30秒前
JasperChan发布了新的文献求助10
30秒前
量子星尘发布了新的文献求助10
30秒前
楠小秾完成签到,获得积分10
30秒前
34秒前
34秒前
Ava应助拼搏梦旋采纳,获得10
34秒前
35秒前
可爱deyi发布了新的文献求助10
38秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971469
求助须知:如何正确求助?哪些是违规求助? 3516210
关于积分的说明 11181332
捐赠科研通 3251376
什么是DOI,文献DOI怎么找? 1795810
邀请新用户注册赠送积分活动 876051
科研通“疑难数据库(出版商)”最低求助积分说明 805245